




Accommodating Intraocular Lens and Conversion Plate

D. JACKSON COLEMAN
WCMC OPTHALMOLOGY
ADRIAN GLASSER (IOL ONLY)
UNIVERSITY OF HOUSTON










The eye focuses via "accommodation", in which the lens changes shape. A conundrum: when the ciliary muscle is relaxed, the lens is stretched and flat (distance viewing); when the ciliary muscle contracts, the lens relaxes to a rounder shape (close viewing)



Mechanism for Accommodation?


- A debate is ciliary muscle the primary driver, or is pressure from vitreous (caused by compression of sclera) most important?
- Affects design of accommodating IOLs.



Most are like this – have "wings" that allow ciliary muscle to change shape



IOL designed under theory that accomodation is driven by vitreous pressure



Can develop
separate
"conversion plates"
to allow other
companies'
lenses to
accommodate via
vitreous as well



Current IOL designs	Coleman/Glasser solution
Single unit must address both capsular bag size and dioptric lens power	Two piece design with separate optic and haptic plate – haptic plate is toroidal, flexible, and porous or fenestrated
Requires large inventory or less than optimal sizing	Lower inventory cost; Allows for optimal sizing in capsular bag <u>and</u> optimal sizing for dioptric lens power
Winged haptic design	360° of continuous haptic support and larger contact surface area between haptic/optic and vitreous provide greater stability and improved accommodative performance
The removal or replacement of traditional IOLs is made very difficult by fibrosis of the lens/haptic to the capsular/zonular support structure. (e.g. in pediatric setting or rare cases of mis-measurement)	After insertion, optic may be replaced or rotated with less trauma



Indications, Markets, M&A

- Cataracts and Presbyopia
- "Intraocular Lenses Market to Reach \$5.0 billion by 2015, According to New Report by Global Industry Analysts, Inc."
- Interest by big pharma
 - Abbott acquired AMO for \$2.8B in 2009
 - Jan 2010 Novartis announced takeover of Alcon 77% majority worth \$38.5B



Contact & More Information

Bruce Toman

Ph: 212-746-6187

Cell 646-492-9869

toman@cornell.edu

skype: bruce.toman

www.ctl.cornell.edu

Cornell Reference Number: 3233

http://cornell.flintbox.com/public/project/22276/

